{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:19:20Z","timestamp":1788279560310,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    The Phase 3 EPCORE FL\u20101 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab (\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    ) significantly improved response rates and prolonged progression\u2010free survival in patients with relapsed or refractory (\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    ) follicular lymphoma (FL). However, the cost\u2010effectiveness of this combination has not been evaluated. The objective of this study was to assess the cost\u2010effectiveness of epcoritamab plus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    compared with\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    alone for patients with\n                    <jats:italic>r<\/jats:italic>\n                    \/\n                    <jats:italic>r<\/jats:italic>\n                    FL from a US payer perspective. A three\u2010state Markov model was constructed with a 30\u2010year time horizon to compare costs and health outcomes of epcoritamab plus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    versus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    . The primary outcome was the incremental cost\u2010effectiveness ratio (ICER), expressed as cost per quality\u2010adjusted life\u2010year (QALY) gained. Parameter uncertainty was evaluated through one\u2010way sensitivity analysis, probabilistic sensitivity analysis, and scenario analyses. In the base\u2010case analysis, epcoritamab plus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    yielded an additional 3.94 QALYs at an incremental cost of $267,721.01 resulting in an ICER of $67,974.64 per QALY gained compared with\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    alone. In the one\u2010way sensitivity analysis, the ICER ranged from $53,819.80 to $82,129.49 per QALY across all parameters tested. In the probabilistic sensitivity analysis, epcoritamab plus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    had a 100% probability of being cost\u2010effective at a willingness\u2010to\u2010pay (WTP) threshold of $150,000 per QALY. From a US payer perspective, epcoritamab plus\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    is estimated to be a cost\u2010effective treatment option compared with\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    for patients with relapsed or refractory follicular lymphoma at a willingness\u2010to\u2010pay threshold of $150,000 per QALY.\n                  <\/jats:p>","DOI":"10.1002\/hon.70221","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:42:51Z","timestamp":1784180571000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost\u2010Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed\/Refractory Follicular Lymphoma: A US Payer Perspective"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2178-6448","authenticated-orcid":false,"given":"Yongtao","family":"He","sequence":"first","affiliation":[{"name":"Department of Pharmacy The Second Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"Institute of Clinical Pharmacy Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"Institute of Clinical Pharmacy Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"Institute of Clinical Pharmacy Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangke","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"Institute of Clinical Pharmacy Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5315-8141","authenticated-orcid":false,"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy The Second Xiangya Hospital Central South University  Changsha Hunan China"},{"name":"Institute of Clinical Pharmacy Central South University  Changsha Hunan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.02.001"},{"key":"e_1_2_9_3_1","volume-title":"Types of B\u2010cell Lymphoma:Follicular Lymphoma","author":"American Cancer Society"},{"key":"e_1_2_9_4_1","volume-title":"Cancer Stat Facts: NHL\u2014Follicular Lymphoma","author":"National Cancer Institute"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026019"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2023.018"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14401"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02360\u20108"},{"key":"e_1_2_9_10_1","volume-title":"FDA Approves epcoritamab\u2010bysp for Follicular Lymphoma Indications","author":"U.S. Food and Drug Administration"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669\u2010025\u201000577\u2010z"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2352820"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198\u2010012\u20100419\u20102"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955\u2010018\u20101013\u20109"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669\u2010021\u201000316\u20100"},{"key":"e_1_2_9_17_1","volume-title":"Official Site | Pricing and Support","author":"AbbVie Inc. EPKINLY\u00ae (epcoritamab\u2010bysp)"},{"key":"e_1_2_9_18_1","volume-title":"Revlimid (Lenalidomide) Prescribing Information and List Price","author":"Bristol Myers Squibb"},{"key":"e_1_2_9_19_1","volume-title":"Rituxan (Rituximab) Full Prescribing Information and Pricing Resource","author":"Genentech USA I"},{"issue":"3","key":"e_1_2_9_20_1","first-page":"75","article-title":"Real\u2010World Treatment Patterns and Healthcare Costs Among Patients With FL With Early Treatment Failure of First\u2010Line Chemoimmunotherapy","volume":"15","author":"Leslie L. A.","year":"2022","journal-title":"American Health and Drug Benefits"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.04.003"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008097"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer\u20102020\u20100057"},{"key":"e_1_2_9_24_1","unstructured":"Centers for Medicare & Medicaid Services \u201cPhysician Fee Schedule \u201d accessed April 1 2026 https:\/\/www.cms.gov\/medicare\/physician\u2010fee\u2010schedule\/search\/overview."},{"key":"e_1_2_9_25_1","unstructured":"Centers for Medicare & Medicaid Services Clinical Laboratory Fee Schedule accessed April 1 2026 https:\/\/www.cms.gov\/medicare\/payment\/fee\u2010schedules\/clinical\u2010laboratory\u2010fee\u2010schedule\u2010clfs\/files\/25clabq4."},{"key":"e_1_2_9_26_1","unstructured":"Centers for Medicare & Medicaid Services \u201cOctober 2025 Addendum B \u201d accessed April 1 2026 https:\/\/www.cms.gov\/medicare\/payment\/prospective\u2010payment\u2010systems\/hospital\u2010outpatient\u2010pps\/quarterly\u2010addenda\u2010updates\/october\u20102025\u2010addendum\u2010b."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.694429"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","unstructured":"AriasE. J.Xu andK.Kochanek \u201cUnited States Life Tables 2023 \u201d74 no.6(July 2025) 1\u201346 https:\/\/www.cdc.gov\/nchs\/nvss\/index.htm.","DOI":"10.15620\/cdc\/174591"},{"key":"e_1_2_9_29_1","volume-title":"Measuring Price Change in the CPI: Medical Care","author":"Statistics USBoL"},{"key":"e_1_2_9_30_1","unstructured":"National Comprehensive Cancer Network 2024 NCCN Guidelines for Patients: Follicular Lymphoma"},{"key":"e_1_2_9_31_1","unstructured":"National Comprehensive Cancer Network \u201cNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B\u2010Cell Lymphomas \u201d (March 2026) https:\/\/nccn.org."},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010181177"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010186548"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010021\u201001052\u20103"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00067"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010018\u20103501\u20108"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70221","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:36:44Z","timestamp":1788277004000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/hon.70221"],"URL":"https:\/\/doi.org\/10.1002\/hon.70221","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70221"}}